<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01450800</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00025269</org_study_id>
    <secondary_id>3913577</secondary_id>
    <nct_id>NCT01450800</nct_id>
  </id_info>
  <brief_title>Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI)</brief_title>
  <acronym>STOPP UTI</acronym>
  <official_title>Antibiotic Prophylaxis for Urinary Tract Infection in Patients Requiring Catheterization After Urogynecologic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of patients undergoing gynecologic surgery who require post-operative
      catheterization to determine if prophylactic antibiotic treatment decreases the risk of
      post-operative urinary tract infection in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Population Participants will be recruited from all patients who are planning to undergo
      gynecologic surgery by an attending surgeon in the Division of Urogynecology at Duke
      University Medical Center (DUMC). After enrollment and randomization, the participants will
      take the study drug once daily to start on post-operative day one and continue until the
      participant has stopped catheterizing for up to one week after surgery. The participant will
      also complete a daily diary for one week after surgery to record any catheterization and any
      study drug or additional antibiotic medication taken. We will then follow patients for a
      total of three weeks after surgery to monitor for treatment for UTI. At three weeks after
      surgery the observation period for the participant is complete.

      Sample Size Under the assumption of 80% power and an alpha error of 0.05, we would need 156
      subjects to demonstrate a 66% reduction in risk of UTI (i.e. from 28% to 10%) in those
      undergoing prophylactic antibiotic treatment. Therefore, we aim to recruit a total of 175
      participants to account for participant dropout.

      Study Definitions For our study purposes, post-operative catheterization will be defined to
      include patients who are hospitalized post-operatively with an indwelling Foley catheter as
      well as patients discharged with either intermittent self-catheterization (ISC) or indwelling
      Foley catheter. The decision to catheterize will be determined by type of surgical procedure,
      need for inpatient stay and void trial results. Void trials will be conducted as follows: the
      bladder is backfilled with 300cc normal saline, the catheter is removed and the patient is
      prompted to void immediately and, after voiding is complete, a (PVR) post-void residual
      volume is measured. The patient passes the void trial if she voids over 200cc in total volume
      or if her PVR is less than 100cc.

      Our primary outcome of treatment for UTI within the first three weeks after surgery is to be
      defined clinically. A patient will be considered to have received treatment for UTI if she
      receives any antibiotic therapy for clinically suspected or culture-proven urinary tract
      infection (i.e. empirically given upon development of urinary symptoms or prescribed based on
      urinalysis or urine culture results) within the first three weeks after surgery.

      Data Collection Demographic characteristics, operative data and post-operative data will be
      collected. Prior to discharge after surgery all patients will undergo a void trial per
      standard procedure unless they receive an indwelling Foley catheter for overnight
      hospitalization. Post-operatively all subjects will be given a catheterization diary to
      record days of catheterization and days of antibiotic therapy. All subjects will be
      instructed to call our clinical office to report any urinary complaints and/or treatment for
      UTI. Information will be collected from electronic medical records regarding any office
      visits, urine cultures performed or treatment for UTI during this post-operative period. Data
      will be entered into a de-identified study database for analysis by the PI and study
      coordinator who will be blinded to participant randomization.

      Subject Randomization and Blinding Study participants will be randomized to prophylactic
      treatment versus no treatment via a computerized randomization scheme by the IDS at the time
      of enrollment. Patients will be blinded to treatment by the utilization of placebo tablets.

      Adverse Events Nitrofurantoin is FDA approved for the treatment of UTI. We will be using a
      prophylactic dose and will monitor for any adverse events. Adverse events will be reported
      per protocol. A safety monitoring designee will perform reviews on a designated basis
      throughout the study.

      Study Costs There will be no additional cost to the patient for their participation in this
      study. No additional laboratory testing will be performed as a result of participation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Tract Infections</measure>
    <time_frame>three weeks post-operative</time_frame>
    <description>The primary outcome was treatment for UTI within the first 3 weeks after surgery. Treatment for UTI was defined to include any treatment received for clinically suspected or culture-proven urinary tract infection within 3 weeks of surgery. Clinically suspected treatment was defined to include treatment given empirically upon development of urinary symptoms or prescribed based on urine test results. Culture-proven UTI was defined as a urine culture with greater than 100,000 colony-forming units of a single organism.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other Risk Factors for UTI</measure>
    <time_frame>3 weeks following surgery</time_frame>
    <description>We examined risk of UTI as related to vaginal estrogen therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Risk Factors for UTI</measure>
    <time_frame>3 weeks following surgery</time_frame>
    <description>We examined risk of UTI as related to history of recurrent UTIs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Risk Factors for UTI</measure>
    <time_frame>3 weeks following surgery</time_frame>
    <description>We examined risk of UTI as related to preoperative UTI treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Risk Factors for UTI</measure>
    <time_frame>3 weeks following surgery</time_frame>
    <description>We examined risk of UTI as related to Creatinine Clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Risk Factors for UTI</measure>
    <time_frame>3 weeks following surgery</time_frame>
    <description>We examined risk of UTI as related to sling as part of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Risk Factors for UTI</measure>
    <time_frame>3 weeks following surgery</time_frame>
    <description>We examined risk of UTI as related to total postoperative catheter days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Risk Factors for UTI</measure>
    <time_frame>3 weeks following surgery</time_frame>
    <description>We examined risk of UTI as related to postoperative catheter type</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Antibiotic Resistance to Macrobid</measure>
    <time_frame>6 weeks after surgery</time_frame>
    <description>We examined for macrobid resistance on urine culture results within 3 weeks of surgery</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">163</enrollment>
  <condition>Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>Nitrofurantoin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nitrofurantoin 100mg by mouth daily starting on postoperative day 1 for up to 7 days during catheterization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo drug 1 tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrofurantoin</intervention_name>
    <description>Nitrofurantoin 100mg po daily to be taken every day the patient uses a catheter for up to one week post-operatively</description>
    <arm_group_label>Nitrofurantoin</arm_group_label>
    <other_name>Macrobid</other_name>
    <other_name>Macrodantin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants randomized to placebo will be instructed to take placebo one tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo medication</other_name>
    <other_name>Inactive medication</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergoing urogynecologic surgery

          -  Receive postoperative catheterization

        Exclusion Criteria:

          -  Age less than 21 years old

          -  Pregnancy

          -  Allergy, contraindication or intolerance to Nitrofurantoin

          -  Do not speak English

          -  Dependent on trans-urethral catheter to accomplish voiding preoperatively

          -  Undergoing interstim device placement, urethral diverticulum surgery or fistula
             surgery

          -  Sustain intraoperative urinary tract injury requiring postoperative catheterization
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cindy Amundsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brown JS, Grady D, Ouslander JG, Herzog AR, Varner RE, Posner SF. Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Heart &amp; Estrogen/Progestin Replacement Study (HERS) Research Group. Obstet Gynecol. 1999 Jul;94(1):66-70.</citation>
    <PMID>10389720</PMID>
  </reference>
  <reference>
    <citation>Hannestad YS, Rortveit G, Sandvik H, Hunskaar S; Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trøndelag. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trøndelag. J Clin Epidemiol. 2000 Nov;53(11):1150-7.</citation>
    <PMID>11106889</PMID>
  </reference>
  <reference>
    <citation>Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5. Epub 2006 Oct 2.</citation>
    <PMID>17049716</PMID>
  </reference>
  <reference>
    <citation>Thomas TM, Plymat KR, Blannin J, Meade TW. Prevalence of urinary incontinence. Br Med J. 1980 Nov 8;281(6250):1243-5.</citation>
    <PMID>7427654</PMID>
  </reference>
  <reference>
    <citation>Wu JM, Hundley AF, Fulton RG, Myers ER. Forecasting the prevalence of pelvic floor disorders in U.S. Women: 2010 to 2050. Obstet Gynecol. 2009 Dec;114(6):1278-83. doi: 10.1097/AOG.0b013e3181c2ce96.</citation>
    <PMID>19935030</PMID>
  </reference>
  <reference>
    <citation>Levin I, Groutz A, Gold R, Pauzner D, Lessing JB, Gordon D. Surgical complications and medium-term outcome results of tension-free vaginal tape: a prospective study of 313 consecutive patients. Neurourol Urodyn. 2004;23(1):7-9.</citation>
    <PMID>14694449</PMID>
  </reference>
  <reference>
    <citation>Nilsson CG, Kuuva N, Falconer C, Rezapour M, Ulmsten U. Long-term results of the tension-free vaginal tape (TVT) procedure for surgical treatment of female stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2001;12 Suppl 2:S5-8.</citation>
    <PMID>11450979</PMID>
  </reference>
  <reference>
    <citation>Falagas ME, Athanasiou S, Iavazzo C, Tokas T, Antsaklis A. Urinary tract infections after pelvic floor gynecological surgery: prevalence and effect of antimicrobial prophylaxis. A systematic review. Int Urogynecol J Pelvic Floor Dysfunct. 2008 Aug;19(8):1165-72. doi: 10.1007/s00192-008-0584-0. Epub 2008 Apr 10. Review.</citation>
    <PMID>18401538</PMID>
  </reference>
  <reference>
    <citation>Sutkin G, Lowder JL, Smith KJ. Prophylactic antibiotics to prevent urinary tract infection during clean intermittent self-catheterization (CISC) for management of voiding dysfunction after prolapse and incontinence surgery: a decision analysis. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Aug;20(8):933-8. doi: 10.1007/s00192-009-0885-y. Epub 2009 Apr 10.</citation>
    <PMID>19582384</PMID>
  </reference>
  <reference>
    <citation>Macy E, Poon K-Y T. Self-reported antibiotic allergy incidence and prevalence: age and sex effects. Am J Med. 2009 Aug;122(8):778.e1-7. doi: 10.1016/j.amjmed.2009.01.034.</citation>
    <PMID>19635279</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2011</study_first_posted>
  <results_first_submitted>September 30, 2013</results_first_submitted>
  <results_first_submitted_qc>March 31, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 1, 2014</results_first_posted>
  <last_update_submitted>December 23, 2016</last_update_submitted>
  <last_update_submitted_qc>December 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>urinary tract infection</keyword>
  <keyword>gynecologic surgery</keyword>
  <keyword>post-operative complications</keyword>
  <keyword>nitrofurantoin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Nitrofurantoin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients who received postoperative transurethral catheterization after surgery for pelvic organ prolapse, urinary incontinence, or both by the Division of Urogynecology at Duke University Medical Center from 8/2011 through 2/2013 were identified, recruited and enrolled after providing written informed consent at a routine pre-operative visit.</recruitment_details>
      <pre_assignment_details>Randomization occurred within a few hours after surgery. Participants were excluded prior to randomization if they sustained intraoperative injury to the urinary tract requiring prolonged catheterization, or if they passed an immediate void trial on day of surgery (as these participants did not receive additional postoperative catheterization).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nitrofurantoin</title>
          <description>Randomized to nitrofurantoin 100mg daily for each day of catheterization for up to 7 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Randomized to placebo 1 tablet daily for each day of catheterization for up to 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82">82 participants were randomized to nitrofurantoin</participants>
                <participants group_id="P2" count="81">81 participants were randomized to placebo</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>163 participants were randomized, 82 to nitrofurantoin and 81 to placebo. Four randomized participants were excluded from the final analysis. One in the placebo group was excluded, as she had previously been included in the study during a prior surgery. Three participants in the nitrofurantoin group were excluded due to protocol deviations.</population>
      <group_list>
        <group group_id="B1">
          <title>Nitrofurantoin</title>
          <description>Participants randomized to receive antibiotics instructed to take nitrofurantoin 100mg by mouth daily starting on postoperative day 1 for up to 7 days during catheterization</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants randomized to receive placebo instructed to take placebo 1 tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="81"/>
            <count group_id="B3" value="163"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="13"/>
                    <measurement group_id="B2" value="57" spread="13"/>
                    <measurement group_id="B3" value="57" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urinary Tract Infections</title>
        <description>The primary outcome was treatment for UTI within the first 3 weeks after surgery. Treatment for UTI was defined to include any treatment received for clinically suspected or culture-proven urinary tract infection within 3 weeks of surgery. Clinically suspected treatment was defined to include treatment given empirically upon development of urinary symptoms or prescribed based on urine test results. Culture-proven UTI was defined as a urine culture with greater than 100,000 colony-forming units of a single organism.</description>
        <time_frame>three weeks post-operative</time_frame>
        <population>Intent-to-treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Nitrofurantoin</title>
            <description>Randomized to nitrofurantoin 100mg daily while using a catheter for up to 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Randomized to placebo 1 tab daily while using a catheter for up to 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Tract Infections</title>
          <description>The primary outcome was treatment for UTI within the first 3 weeks after surgery. Treatment for UTI was defined to include any treatment received for clinically suspected or culture-proven urinary tract infection within 3 weeks of surgery. Clinically suspected treatment was defined to include treatment given empirically upon development of urinary symptoms or prescribed based on urine test results. Culture-proven UTI was defined as a urine culture with greater than 100,000 colony-forming units of a single organism.</description>
          <population>Intent-to-treat analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Risk Factors for UTI</title>
        <description>We examined risk of UTI as related to vaginal estrogen therapy</description>
        <time_frame>3 weeks following surgery</time_frame>
        <population>Used entire study population to determine risk factors for UTI</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants in Final Analysis</title>
            <description>All participants in the final analysis were examined</description>
          </group>
        </group_list>
        <measure>
          <title>Other Risk Factors for UTI</title>
          <description>We examined risk of UTI as related to vaginal estrogen therapy</description>
          <population>Used entire study population to determine risk factors for UTI</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>participants with no UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participants with UTI not on vaginal estrogen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participants with UTI on vaginal estrogen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Risk Factors for UTI</title>
        <description>We examined risk of UTI as related to history of recurrent UTIs</description>
        <time_frame>3 weeks following surgery</time_frame>
        <population>Used entire study population to determine risk factors for UTI</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants in Final Analysis</title>
            <description>All participants in the final analysis were examined</description>
          </group>
        </group_list>
        <measure>
          <title>Other Risk Factors for UTI</title>
          <description>We examined risk of UTI as related to history of recurrent UTIs</description>
          <population>Used entire study population to determine risk factors for UTI</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>participants with no UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participants with UTI with recurrent UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participants with UTI with no recurrent UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Risk Factors for UTI</title>
        <description>We examined risk of UTI as related to preoperative UTI treatment</description>
        <time_frame>3 weeks following surgery</time_frame>
        <population>Used entire study population to determine risk factors for UTI</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants in Final Analysis</title>
            <description>All participants in the final analysis were examined</description>
          </group>
        </group_list>
        <measure>
          <title>Other Risk Factors for UTI</title>
          <description>We examined risk of UTI as related to preoperative UTI treatment</description>
          <population>Used entire study population to determine risk factors for UTI</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>participants without UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participants with UTI with preoperative UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participants with UTI with no preoperative UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Risk Factors for UTI</title>
        <description>We examined risk of UTI as related to Creatinine Clearance</description>
        <time_frame>3 weeks following surgery</time_frame>
        <population>Used entire study population to determine risk factors for UTI</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants in Final Analysis</title>
            <description>All participants in the final analysis were examined</description>
          </group>
        </group_list>
        <measure>
          <title>Other Risk Factors for UTI</title>
          <description>We examined risk of UTI as related to Creatinine Clearance</description>
          <population>Used entire study population to determine risk factors for UTI</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115" spread="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants without UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Risk Factors for UTI</title>
        <description>We examined risk of UTI as related to sling as part of surgery</description>
        <time_frame>3 weeks following surgery</time_frame>
        <population>Used entire study population to determine risk factors for UTI</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants in Final Analysis</title>
            <description>All participants in the final analysis were examined</description>
          </group>
        </group_list>
        <measure>
          <title>Other Risk Factors for UTI</title>
          <description>We examined risk of UTI as related to sling as part of surgery</description>
          <population>Used entire study population to determine risk factors for UTI</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>participants with no UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participants with UTI with sling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participants with UTI with no sling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Risk Factors for UTI</title>
        <description>We examined risk of UTI as related to total postoperative catheter days</description>
        <time_frame>3 weeks following surgery</time_frame>
        <population>Used entire study population to determine risk factors for UTI</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants in Final Analysis</title>
            <description>All participants in the final analysis were examined</description>
          </group>
        </group_list>
        <measure>
          <title>Other Risk Factors for UTI</title>
          <description>We examined risk of UTI as related to total postoperative catheter days</description>
          <population>Used entire study population to determine risk factors for UTI</population>
          <units>days of catheterization</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participants without UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Risk Factors for UTI</title>
        <description>We examined risk of UTI as related to postoperative catheter type</description>
        <time_frame>3 weeks following surgery</time_frame>
        <population>Used entire study population to determine risk factors for UTI</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants in Final Analysis</title>
            <description>All participants in the final analysis were examined</description>
          </group>
        </group_list>
        <measure>
          <title>Other Risk Factors for UTI</title>
          <description>We examined risk of UTI as related to postoperative catheter type</description>
          <population>Used entire study population to determine risk factors for UTI</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>participants without UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participants with UTI with Foley</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participants with UTI with self-catheterization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Antibiotic Resistance to Macrobid</title>
        <description>We examined for macrobid resistance on urine culture results within 3 weeks of surgery</description>
        <time_frame>6 weeks after surgery</time_frame>
        <population>Examined urine cultures with susceptibility testing results for all participants who had positive urine culture results</population>
        <group_list>
          <group group_id="O1">
            <title>Urine Cultures Performed</title>
            <description>All participants in the final analysis were examined</description>
          </group>
        </group_list>
        <measure>
          <title>Antibiotic Resistance to Macrobid</title>
          <description>We examined for macrobid resistance on urine culture results within 3 weeks of surgery</description>
          <population>Examined urine cultures with susceptibility testing results for all participants who had positive urine culture results</population>
          <units>urine culture resistant to nitrofurantoi</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>20 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nitrofurantoin</title>
          <description>Participants randomized to receive nitrofurantoin 100mg by mouth daily each day of catheterization for up to one week after surgery</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants randomized to receive placebo 1 tablet by mouth daily each day of catheterization for up to one week after surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations of our study include recall bias and selection bias. Our findings have limited applicability to elderly patients undergoing pelvic reconstructive surgery.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Alexis Dieter</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-401-1006</phone>
      <email>alexis.dieter@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

